U.S. markets closed

Tetra Bio-Pharma Inc. (JAM1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.2435+0.0075 (+3.18%)
At close: 7:12PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.2360
Open0.2360
Bid0.0000 x 4074100
Ask0.0000 x 2558200
Day's Range0.2360 - 0.2435
52 Week Range0.0790 - 0.3525
Volume9,524
Avg. Volume28,556
Market Cap92.547M
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.0770
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Next Super Stocks on the Move: Tetra Bio-Pharma, Red Light Holland, FansUnite, and Skylight Health

      Trending Sectors in Focus: Sports Betting, I-Gaming, Psychedelics, Healthcare, and Biopharma InnovationNEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestrea

    • Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
      ACCESSWIRE

      Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 * The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenueOTTAWA, ON / ACCESSWIRE / June 2, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today tha

    • Tetra Bio-Pharma Announces Voting Results of 2021 Annual General and Special Meeting
      CNW Group

      Tetra Bio-Pharma Announces Voting Results of 2021 Annual General and Special Meeting

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that all matters presented for approval at the Company's annual general and special meeting (the "Meeting") of shareholders of the Company held earlier today via live audio webcast online were approved.